Test/action/questionnaires conducted at baseline and 6 months
| Clinical examination | Cardiovascular/respiratory/gastrointestinal/nervous system/feet |
| Blood pressure and heart rate | |
| Height, weight, waist circumference | |
| Body fat content (bioimpedance) | |
| Non-fasting blood | HbA1c |
| FBC | |
| Liver/renal function | |
| GAD, IA-2 and zinc transporter autoantibodies (6-month assessment only) | |
| C peptide (baseline only) | |
| Questionnaires | Clarke's Hypoglycemia Awareness Questionnaire |
| The Hypoglycemia Fear Survey | |
| Gold score, Edinburgh hypo survey, and hypoawareness score | |
| Problem Areas in Diabetes (PAID) scale | |
| Diabetes Distress Scale for Adults with Type 1 Diabetes (T1-DDS) | |
| Barriers to Physical Activity in Type 1 Diabetes (BAPAD-1) scale | |
| EQ-5D | |
| Purpose-designed diaries | Blood glucose monitoring diary |
| Insulin monitoring diary | |
| Activity diary | |
| Activity monitor | Small electronic device worn on wrist for 7 days. Measures physical activity by continually monitoring and recording movements of the body. |
| Hypoglycemia | 4-week download of blood glucose monitor |
| Continuous glucose monitor | Wearing a monitor on stomach that continuously records glucose every 5 min for 7 days (optional) |
| Telephone call | Participants telephoned to inform them which treatment arm they had been allocated to |
| Clinical review | Review by nurse, dietitian and doctor to ensure no changes need to be made to insulin dosages or medication |
| Participant postcard | Postcard given at last visit for participant to provide anonymous feedback on the study |
EQ-5D, EuroQol-5 Dimension; FBC, full blood count; GAD, glutamic acid decarboxylase ; IA-2, islet tyrosine phosphate 2.